Legacy Offshore LLC, 100 Enterprise Ave, League City, TX 77573, US

Bio-Path Holdings is an oncology-focused biotechnology company based in Bellaire, TX, that utilizes its innovative DNAbilize platform technology to deliver DNA therapeutics directly to cancer cells. Their mission is to develop targeted cancer treatments that offer effective therapy without harsh side effects, providing previously untreatable cancer patients with a fighting chance. With a pipeline consisting of antisense RNAi nanoparticle drugs, Bio-Path is dedicated to meeting the need for non-toxic therapies for fragile cancer patients who are ineligible for high-dose chemotherapy. Their lead candidate, prexigebersen Liposomal Grb2 Antisense, is currently being assessed in a Phase 2 trial for the treatment of acute myeloid leukemia, while their second product, BP1002 Liposomal Bcl-2 Antisense, is undergoing Phase 1 trials in lymphoma and AML.Generated from the website

Elena Geppert, MD - Harbour Plastic Surgery

Gematics

Worldlive

Harbour Plastic Surgery